Of the approximately 80 million insecticide-treated nets distributed through Global Fund–supported programmes in 2012, about 66 million (73%) went to sub-Saharan African countries. This is well below half the 150 million insecticide-treated nets that the World Health Organisation estimates are needed annually to protect all populations at risk of malaria in this region.
You are here
TB mortality has decreased significantly since 2000 and treatment success rates have shown steady improvement. More than half of the countries that have received Global Fund support are on track to meet the international targets for case detection, treatment success, and TB disease incidence. However, multi-drug-resistant TB (MDR-TB) remains a critical threat.
Significant progress has been achieved in providing antiretroviral therapy (ART) and preventing mother-to-child transmission of HIV (PMTCT), but low antenatal care coverage and other health systems and gender-related challenges are hampering further progress on these fronts.
In preparation for the Fourth Replenishment meetings, the Global Fund has a published an “Update on Results and Impact.” This article provides some of the highlights of the report; more details are provided in separate articles on each of the three diseases.
One of the components of the Global Fund’s evaluation strategy is a system of country reviews conducted with partner organisations. The reviews will assess (1) disease outcomes and impact; (2) the contribution of the Global Fund to these outcomes and impacts; and (3) what factors helped to bring about the changes in outcomes and impact. The last item is referred to by researchers as “causation.”
From now on, annual disbursement decisions and semi-annual reporting will be adopted for all Global Fund grants. The only exception will be for grants whose risk profile requires shorter disbursement decisions or more frequent reporting.
These are part of the changes introduced in February 2013 as part of the Global Fund’s Better Grants for Improved Impact Project.
The Global Fund Board has approved Phase 2 funding for a Round 9 HIV grant in Bosnia and Hercegovina in the amount of $13.5 million. The principal recipient (PR) for the grant is the United Nations Development Programme (UNDP). UNDP is also PR for another HIV grant, which has been essentially completed, and for a TB grant in Bosnia and Hercegovina.
The Global Fund has released its results report for 2012, entitled “Strategic Investments for Impact.” The 94-page report provides comprehensive information on the achievements of programmes supported by the Global Fund through June 2012, and discusses some of the strategic issues the Fund is currently addressing.
This article provides information on some of the major organisations providing Global Fund-focused technical assistance (TA). The article highlights two types of Global Fund-focused TA: (1) TA to help applicants with the development of their Global Fund proposals for Round 11; and (2) TA for programme implementation and institutional development.